



























## REFERENCES

- Hayes JD, Pulford DJ. The glutathione *S*-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev Biochem Mol Biol* 1995;30:445–600.
- Landi S. Mammalian class theta GST and differential susceptibility to carcinogens: a review. *Mutat Res* 2000;463:247–83.
- Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu Rev Pharmacol Toxicol* 2005;45:51–88.
- Eaton DL, Bammler TK. Concise review of the glutathione *S*-transferases and their significance to toxicology. *Toxicol Sci* 1999;49:156–64.
- Tan KL, Webb GC, Baker RT, et al. Molecular cloning of a cDNA and chromosomal localization of a human theta-class glutathione *S*-transferase gene (*GSTT2*) to chromosome 22. *Genomics* 1995;25:381–7.
- Webb G, Vaska V, Coggan M, et al. Chromosomal localization of the gene for the human theta class glutathione transferase (*GSTT1*). *Genomics* 1996;33:121–3.
- Meyer DJ. Significance of an unusually low *K<sub>m</sub>* for glutathione in glutathione transferases of the alpha, mu and pi classes. *Xenobiotica* 1993;23:823–34.
- Jemth P, Mannervik B. Kinetic characterization of recombinant human glutathione transferase T1-1, a polymorphic detoxication enzyme. *Arch Biochem Biophys* 1997;348:247–54.
- Juronen E, Tasa G, Uuskula M, et al. Purification, characterization and tissue distribution of human class theta glutathione *S*-transferase T1-1. *Biochem Mol Biol Int* 1996;39:21–9.
- Coggan M, Whitbread L, Whittington A, et al. Structure and organization of the human theta-class glutathione *S*-transferase and D-dopachrome tautomerase gene complex. *Biochem J* 1998;334:617–23.
- Hirvonen A. Genetic factors in individual responses to environmental exposures. *J Occup Environ Med* 1995;37:37–43.
- Wiencke JK, Kelsey KT, Lamela RA, et al. Human glutathione *S*-transferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. *Cancer Res* 1990;50:1585–90.
- Norppa H, Hirvonen A, Jarventaus H, et al. Role of *GSTT1* and *GSTM1* genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. *Carcinogenesis* 1995;16:1261–4.
- Prochaska HJ, Santamaria AB, Talalay P. Rapid detection of inducers of enzymes that protect against carcinogens. *Proc Natl Acad Sci U S A* 1992;89:2394–8.
- Lin HJ, Probst-Hensch NM, Louie AD, et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. *Cancer Epidemiol Biomarkers Prev* 1998;7:647–52.
- Zhang Y, Kolm RH, Mannervik B, et al. Reversible conjugation of isothiocyanates with glutathione catalyzed by human glutathione transferases. *Biochem Biophys Res Commun* 1995;206:748–55.
- London SJ, Yuan JM, Chung FL, et al. Isothiocyanates, glutathione *S*-transferase *M1* and *T1* polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China. *Lancet* 2000;356:724–9.
- Sprenger R, Schlagenhauser R, Kerb R, et al. Characterization of the glutathione *S*-transferase *GSTT1* deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. *Pharmacogenetics* 2000;10:557–65.
- Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione *S*-transferase theta (*GSTT1*): cDNA cloning and the characterization of a genetic polymorphism. *Biochem J* 1994;300:271–6.
- Hallier E, Langhof T, Dannappel D, et al. Polymorphism of glutathione conjugation of methyl bromide, ethylene oxide and dichloromethane in human blood: influence on the induction of sister chromatid exchanges (SCE) in lymphocytes. *Arch Toxicol* 1993;67:173–8.
- Alexandrie AK, Rannug A, Juronen E, et al. Detection and characterization of a novel functional polymorphism in the *GSTT1* gene. *Pharmacogenetics* 2002;12:613–19.
- Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. *Cancer Epidemiol Biomarkers Prev* 2001;10:1239–48.
- Nelson HH, Wiencke JK, Christiani DC, et al. Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione *S*-transferase theta. *Carcinogenesis* 1995;16:1243–5.
- Warholm M, Alexandrie AK, Högberg J, et al. Polymorphic distribution of glutathione transferase activity with methyl chloride in human blood. *Pharmacogenetics* 1994;4:307–11.
- Strange RC, Spiteri MA, Ramachandran S, et al. Glutathione-*S*-transferase family of enzymes. *Mutat Res* 2001;482:21–6.
- Bao Y, Jemth P, Mannervik B, et al. Reduction of thymine hydroperoxide by phospholipids hydroperoxide glutathione peroxidase and glutathione transferases. *FEBS Lett* 1997;410:210–12.
- Whittington A, Vichai V, Webb G, et al. Gene structure, expression and chromosomal localization of murine theta class glutathione transferase mGSTT1-1. *Biochem J* 1999;337:141–51.
- Meyer DJ, Coles B, Pemble SE, et al. Theta, a new class of glutathione transferases purified from rat and man. *Biochem J* 1991;274:409–14.
- Chamberlain MP, Lock EA, Gaskell BA, et al. The role of glutathione *S*-transferase- and cytochrome P450-dependent metabolism in the olfactory toxicity of methyl iodide in the rat. *Arch Toxicol* 1998;72:420–8.
- DeMarini DM, Shelton ML, Warren SH, et al. Glutathione *S*-transferase-mediated induction of GC→AT transitions by halomethanes in *Salmonella*. *Environ Mol Mutagen* 1997;30:440–7.
- Shimada T, Yamazaki H, Oda Y, et al. Activation and inactivation of carcinogenic dihaloalkanes and other compounds by glutathione *S*-transferase 5-5 in *Salmonella typhimurium* tester strain NM5004. *Chem Res Toxicol* 1996;9:333–40.
- Sherratt PJ, Pulford DJ, Harrison DJ, et al. Evidence that human class Theta glutathione *S*-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Comparison of the tissue distribution of GST T1-1 with that of classes Alpha, Mu and Pi GST in human. *Biochem J* 1997;326:837–46.
- Hallier E, Schroeder KR, Asmuth K, et al. Metabolism of dichloromethane (methylene chloride) to formaldehyde in human erythrocytes: influence of polymorphism of glutathione transferase theta (*GSTT1-1*). *Arch Toxicol* 1994;68:423–7.
- Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. *Int J Cancer* 2001;94:153–6.
- Parkin DM, Whelan SL, Ferlay J, et al, eds. Cancer incidence in five continents. Vol VIII. Lyon, France: International Agency for Research on Cancer, 2002. (IARC scientific publication no. 155).

36. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. *J Natl Cancer Inst* 1999;91:675–90.
37. Wynder EL, Muscat JE. The changing epidemiology of smoking and lung cancer histology. *Environ Health Perspect* 1995;103:143–8.
38. Travis WD, Lubin J, Ries L, et al. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. *Cancer* 1996;77:2464–70.
39. Charloux A, Quoix E, Wolkove N, et al. The increasing incidence of lung adenocarcinoma: reality or artifact? A review of the epidemiology of lung adenocarcinoma. *Int J Epidemiol* 1997;26:14–23.
40. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. *Lancet* 2003;362:847–52.
41. Becher H, Jockel KH, Timm J, et al. Smoking cessation and nonsmoking intervals: effect of different smoking patterns on lung cancer risk. *Cancer Causes Control* 1991;2:381–7.
42. Zhong L, Goldberg MS, Parent ME, et al. Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis. *Lung Cancer* 2000;27:3–18.
43. Willett WC. Diet, nutrition, and avoidable cancer. *Environ Health Perspect* 1995;103(suppl 8):165–70.
44. Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. *Br Med Bull* 2003;68:71–94.
45. National Research Council (NBC). Committee on Health Risks of Exposures to Radon, Board on Radiation Effects Research. Health effects of exposure to radon (BEIR VI). Washington, DC: National Academy Press, 1988.
46. Reszka E, Wasowicz W. Significance of genetic polymorphisms in glutathione *S*-transferase multigene family and lung cancer risk. *Int J Occup Med Environ Health* 2001;14:99–113.
47. Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in *CYP1A1*, *GSTM1*, *GSTT1* and lung cancer below the age of 45 years. *Int J Epidemiol* 2003;32:60–3.
48. Stucker I, Boffetta P, Antilla S, et al. Lack of interaction between asbestos exposure and glutathione *S*-transferase *M1* and *T1* genotypes in lung carcinogenesis. *Cancer Epidemiol Biomarkers Prev* 2001;10:1253–8.
49. El-Zein R, Zwischenberger JB, Wood TG, et al. Combined genetic polymorphism and risk for development of lung cancer. *Mutat Res* 1997;381:189–200.
50. El-Zein R, Conforti-Froes N, Au WW. Interactions between genetic predisposition and environmental toxicants for development of lung cancer. *Environ Mol Mutagen* 1997;30:196–204.
51. El-Zein RA, Zwischenberger JB, Abdel-Rahman SZ, et al. Polymorphism of metabolizing genes and lung cancer histology: prevalence of *CYP2E1* in adenocarcinoma. *Cancer Lett* 1997;112:71–8.
52. Kelsey KT, Spitz MR, Zuo ZF, et al. Polymorphisms in the glutathione *S*-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States). *Cancer Causes Control* 1997;8:554–9.
53. To-Figueras J, Gene M, Gomez-Catalan J, et al. Glutathione *S*-transferase *M1* (*GSTM1*) and *T1* (*GSTT1*) polymorphisms and lung cancer risk among northwestern Mediterraneans. *Carcinogenesis* 1997;18:1529–33.
54. Lan Q, He X, Costa D, et al. Glutathione *S*-transferase *GSTM1* and *GSTT1* genotypes and susceptibility to lung cancer. *Wei Sheng Yan Jiu* 1999;28:9–11.
55. To-Figueras J, Gene M, Gomez-Catalan J, et al. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione *S*-transferase *P1*. *Cancer Lett* 2001;173:155–62.
56. Cajas-Salazar N, Sierra-Torres CH, Salama SA, et al. Combined effect of *MPO*, *GSTM1* and *GSTT1* polymorphisms on chromosome aberrations and lung cancer risk. *Int J Hyg Environ Health* 2003;206:473–83.
57. Wenzlaff AS, Cote ML, Bock CH, et al. *GSTM1*, *GSTT1* and *GSTP1* polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. *Carcinogenesis* 2005;26:395–401.
58. Cote ML, Kardia SL, Wenzlaff AS, et al. Combinations of glutathione *S*-transferase genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. *Carcinogenesis* 2005;26:811–19.
59. Reszka E, Wasowicz W, Gromadzinska J, et al. Evaluation of selenium, zinc and copper levels related to GST genetic polymorphism in lung cancer patients. *Trace Elem Electrolytes* 2005;22:23–32.
60. Alexandrie AK, Nyberg F, Warholm M, et al. Influence of *CYP1A1*, *GSTM1*, *GSTT1*, and *NQO1* genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. *Cancer Epidemiol Biomarkers Prev* 2004;13:908–14.
61. Belogubova EV, Togo AV, Karpova MB, et al. A novel approach for assessment of cancer predisposing roles of *GSTM1* and *GSTT1* genes: use of putatively cancer resistant elderly tumor-free smokers as the referents. *Lung Cancer* 2004;43:259–66.
62. Harms C, Salama SA, Sierra-Torres CH, et al. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. *Environ Mol Mutagen* 2004;44:74–82.
63. Schneider J, Berges U, Philipp M, et al. *GSTM1*, *GSTT1*, and *GSTP1* polymorphism and lung cancer risk in relation to tobacco smoking. *Cancer Lett* 2004;208:65–74.
64. Sobti RC, Sharma S, Joshi A, et al. Genetic polymorphism of the *CYP1A1*, *CYP2E1*, *GSTM1* and *GSTT1* genes and lung cancer susceptibility in a north Indian population. *Mol Cell Biochem* 2004;266:1–9.
65. Sørensen M, Autrup H, Tjønneland A, et al. Glutathione *S*-transferase *T1* null-genotype is associated with an increased risk of lung cancer. *Int J Cancer* 2004;110:219–24.
66. Dialyna IA, Miyakis S, Georgatou N, et al. Genetic polymorphisms of *CYP1A1*, *GSTM1* and *GSTT1* genes and lung cancer risk. *Oncol Rep* 2003;10:1829–35.
67. Ruano-Ravina A, Figueiras A, Loidi L, et al. *GSTM1* and *GSTT1* polymorphisms, tobacco and risk of lung cancer: a case-control study from Galicia, Spain. *Anticancer Res* 2003;23:4333–7.
68. Lewis SJ, Cherry NM, Niven RM, et al. *GSTM1*, *GSTT1* and *GSTP1* polymorphisms and lung cancer risk. *Cancer Lett* 2002;180:165–71.
69. Stucker I, Hirvonen A, de Waziers I, et al. Genetic polymorphisms of glutathione *S*-transferases as modulators of lung cancer susceptibility. *Carcinogenesis* 2002;23:1475–81.
70. Hou SM, Falt S, Nyberg F. Glutathione *S*-transferase *T1*-null genotype interacts synergistically with heavy smoking on lung cancer risk. *Environ Mol Mutagen* 2001;38:83–6.
71. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and *GSTM1* polymorphisms on histological subtype of non-small cell lung carcinoma. *Cancer Res* 2001;61:8718–22.
72. Risch A, Wikman H, Thiel S, et al. Glutathione-*S*-transferase *M1*, *M3*, *T1* and *P1* polymorphisms and susceptibility to

- non-small-cell lung cancer subtypes and hamartomas. *Pharmacogenetics* 2001;11:757–64.
73. Malats N, Camus-Radon AM, Nyberg F, et al. Lung cancer risk in nonsmokers and *GSTM1* and *GSTT1* genetic polymorphism. *Cancer Epidemiol Biomarkers Prev* 2000;9:827–33.
  74. Spitz MR, Duphorne CM, Detry MA, et al. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione *S*-transferase polymorphisms in lung cancer risk. *Cancer Epidemiol Biomarkers Prev* 2000;9:1017–20.
  75. To-Figueras J, Gene M, Gomez-Catalan J, et al. Genetic polymorphism of glutathione *S*-transferase *P1* gene and lung cancer risk. *Cancer Causes Control* 1999;10:65–70.
  76. Saarikoski ST, Voho A, Reinikainen M, et al. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. *Int J Cancer* 1998;77:516–21.
  77. Salagovic J, Kalina I, Stubna J, et al. Genetic polymorphism of glutathione *S*-transferases *M1* and *T1* as a risk factor in lung and bladder cancers. *Neoplasma* 1998;45:312–17.
  78. Jourenkova N, Reinikainen M, Bouchardy C, et al. Effects of glutathione *S*-transferases *GSTM1* and *GSTT1* genotypes on lung cancer risk in smokers. *Pharmacogenetics* 1997;7:515–18.
  79. Deakin M, Elder J, Hendrickse C, et al. Glutathione *S*-transferase *GSTT1* genotypes and susceptibility to cancer: studies of interactions with *GSTM1* in lung, oral, gastric and colorectal cancers. *Carcinogenesis* 1996;17:881–4.
  80. Chan-Yeung M, Tan-Un KC, Ip MS, et al. Lung cancer susceptibility and polymorphisms of glutathione-*S*-transferase genes in Hong Kong. *Lung Cancer* 2004;45:155–60.
  81. Liang GY, Pu YP, Yin LH. Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. (In Chinese). *Yi Chuan* 2004;26:584–8.
  82. Wang J, Deng Y, Cheng J, et al. GST genetic polymorphisms and lung adenocarcinoma susceptibility in a Chinese population. *Cancer Lett* 2003;201:185–93.
  83. Sunaga N, Kohno T, Yanagitani N, et al. Contribution of the *NQO1* and *GSTT1* polymorphisms to lung adenocarcinoma susceptibility. *Cancer Epidemiol Biomarkers Prev* 2002;11:730–8.
  84. Zhao B, Seow A, Lee EJ, et al. Dietary isothiocyanates, glutathione *S*-transferase *-M1*, *-T1* polymorphisms and lung cancer risk among Chinese women in Singapore. *Cancer Epidemiol Biomarkers Prev* 2001;10:1063–7.
  85. Kiyohara C, Yamamura KI, Nakanishi Y, et al. Polymorphism in *GSTM1*, *GSTT1*, and *GSTP1* and susceptibility to lung cancer in a Japanese population. *Asian Pac J Cancer Prev* 2000;1:293–8.
  86. Lan Q, He X, Costa DJ, et al. Indoor coal combustion emissions, *GSTM1* and *GSTT1* genotypes, and lung cancer risk: a case-control study in Xuan Wei, China. *Cancer Epidemiol Biomarkers Prev* 2000;9:605–8.
  87. Yang P, Bamlet WR, Ebbert JO, et al. Glutathione pathway genes and lung cancer risk in young and old populations. *Carcinogenesis* 2004;25:1935–44.
  88. Nazar-Stewart V, Vaughan TL, Stapleton P, et al. A population-based study of glutathione *S*-transferase *M1*, *T1* and *P1* genotypes and risk for lung cancer. *Lung Cancer* 2003;40:247–58.
  89. Gallegos-Arreola MP, Gomez-Meda BC, Morgan-Villela G, et al. *GSTT1* gene deletion is associated with lung cancer in Mexican patients. *Dis Markers* 2003–2004;19:259–61.
  90. Taioli E. International collaborative study on genetic susceptibility to environmental carcinogens. *Cancer Epidemiol Biomarkers Prev* 1999;8:727–8.
  91. Gaspari L, Marinelli D, Taioli E, et al. International collaborative study on genetic susceptibility to environmental carcinogens (GSEC): an update. *Int J Hyg Environ Health* 2001;204:39–42.
  92. Egger M, Smith D, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
  93. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. *Stat Med* 1999;18:321–59.
  94. Vineis P, Bartsch H, Caporaso N, et al. Genetically based *N*-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. *Nature* 1994;369:154–6.
  95. Garte S, Zocchetti C, Taioli E. Gene-environment interactions in the application of biomarkers of cancer susceptibility in epidemiology. *IARC Sci Publ* 1997;142:251–64.
  96. Hung RJ, Boffetta P, Brockmüller J, et al. *CYP1A1* and *GSTM1* genetic polymorphisms and lung cancer risk in Caucasian nonsmokers: a pooled analysis. *Carcinogenesis* 2003;24:875–82.
  97. Raimondi S, Boffetta P, Anttila S, et al. Metabolic gene polymorphism and lung cancer risk in non-smokers: an update of the GSEC study. *Mutat Res* 2005;592:45–57.
  98. Brockstedt U, Krajcinovic M, Richer C, et al. Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione *S*-transferases (GSTs). *Mutat Res* 2002;516:41–7.
  99. Viezzer C, Norppa H, Clonfero E, et al. Influence of *GSTM1*, *GSTT1*, *GSTP1*, and *EPHX* gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers. *Mutat Res* 1999;431:259–69.
  100. Laffon B, Perez-Cadahia B, Pasaro E, et al. Effect of epoxide hydrolase and glutathione *S*-transferase genotypes on the induction of micronuclei and DNA damage by styrene-7, 8-oxide in vitro. *Mutat Res* 2003;536:49–59.
  101. Yong LC, Schulte PA, Wiencke JK, et al. Hemoglobin adducts and sister chromatid exchanges in hospital workers exposed to ethylene oxide: effects of glutathione *S*-transferase *T1* and *M1* genotypes. *Cancer Epidemiol Biomarkers Prev* 2001;10:539–50.
  102. Marcon F, Andreoli C, Rossi S, et al. Assessment of individual sensitivity to ionizing radiation and DNA repair efficiency in a healthy population. *Mutat Res* 2003;541:1–8.
  103. Scarpato R, Migliore L, Hirvonen A, et al. Cytogenetic monitoring of occupational exposure to pesticides: characterization of *GSTM1*, *GSTT1*, and *NAT2* genotypes. *Environ Mol Mutagen* 1996;27:263–9.
  104. Lodovici M, Luceri C, Guglielmi F, et al. Benzo(a)pyrene diol epoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of *CYP1A1*, *GSTM1*, *GSTP1*, *GSTT1*, and *mEH*. *Cancer Epidemiol Biomarkers Prev* 2004;13:1342–8.
  105. Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. *Int J Epidemiol* 1999;28:1–9.